Cetuximab
- Generic Name
- Cetuximab
- Brand Names
- Erbitux
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 205923-56-4
- Unique Ingredient Identifier
- PQX0D8J21J
- Background
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelia...
- Indication
Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for r...
- Associated Conditions
- Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Metastatic Colorectal Cancer (CRC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Regionally Advanced Squamous Cell Carcinoma of the Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Associated Therapies
- -
Combination Therapy for BRAF-V600E Metastatic CRCm
- Conditions
- Interventions
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Vall d'Hebron Institute of Oncology
- Target Recruit Count
- 94
- Registration Number
- NCT06411600
- Locations
- 🇪🇸
Vall d'Hebron Hospital, Barcelona, Spain
Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC
- Conditions
- Interventions
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Wangxia LV
- Target Recruit Count
- 26
- Registration Number
- NCT06379399
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT06369259
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 42
- Registration Number
- NCT06358430
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 46
- Registration Number
- NCT06332079
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Hansoh BioMedical R&D Company
- Target Recruit Count
- 610
- Registration Number
- NCT06332170
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study of BND-35 in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Biond Biologics
- Target Recruit Count
- 280
- Registration Number
- NCT06274437
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇮🇱Hadassah University Medical Center, Jerusalem, Israel
🇮🇱Rabin Medical Center, Petah Tikva, Israel
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 351
- Registration Number
- NCT06241456
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Ohio State University - Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Yale New Haven Hospital - Yale Cancer Center, New Haven, Connecticut, United States
PD-L1 T-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
- Conditions
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Glenn J. Hanna
- Target Recruit Count
- 25
- Registration Number
- NCT06239220
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- City Clinical Oncology Hospital No 1
- Target Recruit Count
- 355
- Registration Number
- NCT06226857
- Locations
- 🇷🇺
Reutov Clinical hospital, Reutov, Russian Federation
🇷🇺N.N Blokhin Cancer Reserch Center, Moscow, Russian Federation
🇷🇺Moscow Multidiciplinary Clinical Center Kommunarka, Moscow, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.